U.S., June 24 -- ClinicalTrials.gov registry received information related to the study (NCT07663370) titled 'Effectiveness of Biosimilar Ranibizumab in the Management of Diabetic Macular Edema' on June 17.
Brief Summary: Diabetic macular edema (DME) is a leading cause of vision loss in patients with diabetes. Anti-VEGF agents are widely used to improve vision and reduce retinal swelling. However, treatment cost remains a major barrier in many healthcare systems.
This study evaluates the real-world effectiveness and safety of a ranibizumab biosimilar in patients with DME. Medical records of adult patients treated at a tertiary ophthalmology center will be reviewed. Changes in best-corrected visual acuity (BCVA) and central macular thicknes...